Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock

Journal of Critical Care

Volumn 20, Issue 3, 2005, Pages 239-249

  Neilson, Aileen R ^a   Burchardi, Hilmar ^b   Schneider, Heinz ^a  

^a HealthEcon Ltd   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Cost effectiveness; Pentaglobin; Septic shock; Severe sepsis

Indexed keywords

HUMAN ALBUMIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; GERMANY; HEALTH CARE COST; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MATHEMATICAL COMPUTING; META ANALYSIS; MORTALITY; PROBABILITY; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; GERMANY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTENSIVE CARE UNITS; LENGTH OF STAY; SEPSIS; SHOCK, SEPTIC;

EID: 27144436171     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2005.03.003     Document Type: Article

References (28)

1. A. Schmid, H. Burchardi, and J. Clouth Burden of illness imposed by severe sepsis in Germany Eur J Health Econ 3 2002 77 82
2. O. Moerer, A. Schmid, and M. Hofmann Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use Intensive Care Med 28 2002 1440 1446
3. E. Rivers, B. Nguyen, and S. Havstad Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 345 19 2001 1368 1377
4. D. Annane, E. Bellissant, and P.E. Bollaert Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis BMJ 329 2004 480 10.1136/bmj.38181.482222.55 [published 2 August 2004]
5. S. Jacobs, D.A. Price Evans, and M. Tariq Fluconazole improves survival in septic shock: a randomised double-blind prospective study Crit Care Med 31 7 2003 1938 1946
6. G.R. Bernard, J.L. Vincent, and P.F. Laterre Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis N Engl J Med 344 10 2001 699 709
7. M.M. Alejandria, M.A. Lansang, and L.F. Dans Intravenous immunoglobulin for treating sepsis and septic shock [Cochrane Review] The Cochrane Library, Issue 1 2003 John Wiley and Sons Oxford [Update Software]
8. J. Pildal, and P.C. Gøtzsche Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review Clin Infect Dis 39 2004 38 46
9. K.B. Laupland Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults Can J Infect Dis 13 2 2002 100 106
10. L. Smeeth, A. Haines, and S. Ebrahim Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading BMJ 318 1999 1548 1551
11. A.H. Briggs, and A.M. Gray Handling uncertainty when performing economic evaluation of healthcare interventions Health Technol Assess 3 1999 1 134
12. H.M. Just, M. Metzger, and W. Vogel Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomised controlled study Klin Wochenschr 64 1986 245 256
13. C. Wesoly, N. Kipping, and R. Grundmann Immunoglobulin therapy of postoperative sepsis Z Exp Chir Transplant Kunstl Organe 23 1990 213 216
14. J. Schedel, U. Dreikhausen, and B. Nentwig Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial Crit Care Med 19 1991 1104 1113
15. F. Vogel Bewertung der intravenösen IgM-Therapie bei schweren nosokomialen Infektionen (Ergebnisse einer kontrollierten randomisierten Studie) H.H. Deicher W. Schoeppe Klinisch angewandte Immunologie 1988 Springer 30 41
16. G. Behre, H. Ostermann, and I. Schedel Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial Anti-Infective Drugs Chemother 13 2 1995 129 134
17. A. Rodríguez, F. Palizas, and J. Neira Immunoglobulina polivalente en el tratamiento de la sepsis abdominal Med Intensiva 18 2001 11 15
18. S. Karatzas, E. Boutzouka, and K. Venetsanou The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view Crit Care 6 2002 543 544
19. H.B. Reith, and U. Mittelkötter Markers of inflammation for prognosis and therapy control in patients with abdominal sepsis-options for using adjuvant intravenous immunoglobulins E. Faist Immunological screening and immunotherapy in critically ill patients with abdominal infections 2001 Springer Verlag New York, NY 15 38 [Chapter 11]
20. S. Tugrul, P.E. Ozcan, and O. Akinci The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN2886380] Crit Care 6 2002 357 362
21. R.E. Brown, R.A. Henderson, and D. Koster Cost effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial Eur Heart 23 2002 50 58
22. R. Lorenzoni, D. Pagano, and G. Mazzotta Pitfalls in the economic evaluation of thrombolysis of myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups Eur Heart J 19 1998 1518 1524
23. E.S. Dietrich, B. Schubert, and W. Ebner Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection Pharmacoeconomics 19 2001 79 84
24. M. Betancourt, P.S. McKinnon, and R.M. Massanari An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures Pharmacoeconomics 21 2003 1331 1340
25. A.R. Neilson, H. Burchardi, and C. Chinn Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany J Crit Care 18 2003 217 227
26. D.C. Angus, W.T. Linde-Zwirble, and G. Clermont Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Crit Care Med 31 2003 1 11
27. D.G. Altman, and P.K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ 319 1999 1492 1495
28. I.S. Kristiansen, and D. Gyrd-Hansen Cost-effectiveness analysis on the number-needed-to-treat: common sense or non-sense? Health Econ 13 2004 9 19